Results 291 to 300 of about 401,950 (315)

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

Cancer Cell, 2010
Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom   +2 more
exaly  

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Cancer Discovery, 2014
Cath Eberlein, M Raymond V Finlay, Richard A Ward   +2 more
exaly  

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Nature Reviews Clinical Oncology, 2010
Deric L Wheeler, Paul M Harari
exaly  

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Nature Reviews Clinical Oncology, 2018
Gonzalo Recondo, Benjamin Besse, Luc Friboulet   +2 more
exaly  

Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation

Nature, 2011
Weiwei Yang, , Zhimin Lu
exaly  

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Nature Medicine, 2018
Jacqulyne Robichaux, Yasir Y Elamin, Zhi Tan   +2 more
exaly  

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Signal Transduction and Targeted Therapy, 2019
Simon Vyse, Paul H Huang
exaly  

EGFR Mutations

2019
Anna Manzo, Agnese Montanino, Raffaele Costanzo, Claudia Sandomenico, Giuliano Palumbo, Clorinda Schettino, Gennaro Daniele, Alessandro Morabito, Francesco Perrone, Maria Carmela Piccirillo   +9 more
openaire   +1 more source

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

Nature Reviews Clinical Oncology, 2009
Nicola Normanno, Floriana Morgillo, Antonella De Luca   +2 more
exaly  

Afatinib—new therapy option for EGFR-mutant lung cancer

Nature Reviews Clinical Oncology, 2013
Helena A Yu, William Pao
exaly